As reported in a previous pan-cancer study, the biallelic pathogenic alterations of BRCA1/2 accounted for 68.7% of all cases harboring BRCA1/2 mutations, which increased to 89.9% in BRCA-associated cancers [23]. This evidence concerns the gene BRCA1 and cancer.